This lesson is good for 0.2 CE units, with a passing grade of 70%.
Goal
The goal of this program is to inform the participant of costeffective ways to prevent, identify, and manage nausea and vomiting induced by antineoplastic agents.
Objectives
At the completion of this program the participant will be able to:
1. List antineoplastic agents associated with a high incidence of nausea and vomiting.
2. Identify patient-specific risk factors for developing chemotherapyinduced nausea and vomiting (CINV) and how these factors may influence treatment of this syndrome.
3. Compare the three major types of CINV, including the pathophysiologic mechanism, time of onset, and symptom duration of each type.
4. Explain the mechanism of action and appropriate place in therapy for each type of antiemetic agent.
5. Differentiate between pharmacologic regimens for the prevention and treatment of CINV in adults.
6. Identify drug-specific factors that must be considered in developing a formulary management strategy for the antiemetic agents.
7. Describe specific information that the pharmacist can share with patients to help them understand and manage CINV.
LeskoL.M.Psychologic issues. In: DeVitaV.T., HellmanS., RosenbergS.A., eds. Cancer: Principles and Practice of Oncology.5th edition. Philadelphia, PA: Lippincott-Raven Publishers; 1997, 2879–91.
2.
CoatesA., AbrahamS., KayeS.B.On the receiving end—patient perception of the side—effects of cancer chemotherapy. Eur J Cancer Clin Oncol.1983; 19: 203–8.
3.
LindleyC.M., BernardS., FieldsS.M.Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol.1989; 7: 1142–9.
4.
LindleyC.M., HirschJ.D.Nausea and vomiting and cancer patients' quality of life: A discussion of Dr. Selby's paper. Br J Cancer Suppl.1992; 66(suppl 1): S26–9.
5.
BlissJ.M., RobertsonB., SelbyP.J.The impact of nausea and vomiting upon quality of life measures. Br J Cancer Suppl.1992; 66(suppl 1): S14–22; S23.
6.
OsobaD., ZeeB., WarrD.Quality of life studies in chemotherapy-induced emesis. Oncology.1996; 53(suppl 1): 92–5.
7.
OsobaD., ZeeB., WarrD.Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer:1997; 5: 307–13.
8.
ASHP Commission on Therapeutics.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm.1999; 56: 729–64.
9.
BergerA.M., Clark-SnowR.A.Nausea and vomiting. In: DeVitaV.T., HellmanS., RosenbergS.A., eds. Cancer: Principles and Practice of Oncology.5th edition.Philadelphia, PA: Lippincott-Raven Publishers; 1997, 2705–14.
10.
BarbezatG.O.The vomiting patient: A rational approach. Drugs.1981; 22: 246–53.
ChabnerB.A., AllegraC.J., CurtG.A.Antineoplastic agents. In: HardmanJ.G., Lim-birdL.E., MolinoffP.B.., eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics.9th edition.New York, NY: McGraw-Hill Health Professions Division; 1996, 1233–87.
15.
WolffJ.A.First light on the horizon: The dawn of chemotherapy. Med Pediatr Oncol.1999; 33: 405–10.
16.
BertinoJ.R.Ode to methotrexate. J Clin Oncol.1993; 11: 5–14.
17.
CarterS.K.Cancer chemotherapy 1973—present: A personal perspective. J Cancer Res Clin Oncol.1995; 121: 501–4.
18.
TortoriceP.V., O'ConnellM.B.Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy.1990; 10: 129–45.
19.
SeigelL.J., LongoD.L.The control of chemotherapy-induced emesis. Ann Intern Med.1981; 95: 352–9.
20.
MartinM.Myths and realities of antiemetic treatment. Br J Cancer.1992; 66(suppl XIX):S46–S51.
21.
HeskethP.J.Treatment of chemotherapy-induced emesis in the 1990s: Impact of the 5-HT3 receptor antagonists. Support Care Cancer.1994; 2: 286–92.
22.
GriffinA.M., ButowP.N., CoatesA.S.On the receiving end V: Patient perception of the side-effects of cancer chemotherapy in 1993. Ann Oncol.1996; 7: 189–95.
23.
SledgeG.W., EinhornL., NagyC.Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer.1992; 70: 2525–8.
24.
De MulderP.H., RoilaF., KrisM.G.Consensus regarding multiple day and rescue antiemetic therapy. Support Care Cancer.1998; 6: 248–52.
25.
HerrstedtJ.Antiemetic research: A look to the future. Support Care Cancer.1998; 6: 8–12.
Merriam Webster's Collegiate Dictionary. Available online at http://www.bri-tannica.com/bcom/dictionary/. Chicago, IL: Britannica.com Incorporated, Accessed November 8, 2000.
28.
ValleyA.Gastrointestinal complications of cancer chemotherapy. In: FinleyR.S., BalmerC., eds. Concepts in Oncology Therapeutics.2nd edition.Bethesda, MD: American Society of Health-System Pharmacists, Inc., 1998; 147–71.
29.
Dorland's Illustrated Medical Dictionary.28th ed.Philadelphia, PA: W.B. Saunders Company; 1994.
30.
TavorathR., HeskethP.J.Drug treatment of chemotherapy-induced delayed emesis. Drugs.1996; 52: 639–48.
31.
BurkeM.B., WilkesG.M., BergD.Cancer Chemotherapy: A Nursing Process Approach.Boston, MA: Jones and Bartlett Publishers;1991; 91–101.
32.
KrisM.G., RoilaF., De MulderP.H.M.Delayed emesis following anticancer chemotherapy. Support Care Cancer.1998; 6: 228–32.
33.
HeskethP.J., GrallaR.J., du BoisA.Methodology of antiemetic trials: Response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer.1998; 6: 221–7.
34.
GravesT.Emesis as a complication of cancer chemotherapy: Pathophysiology, importance, and treatment. Pharmacotherapy.1992; 12: 337–45.
35.
LindleyC., BlowerP.Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis. Am J Health-Syst Pharm.2000; 57: 1685–97.
36.
Veyrat-FolletC., FarinottiR., PalmerJ.L.Physiology of chemotherapy-induced emesis and antiemetic therapy: Predictive models for evaluation of new compounds. Drugs.1997; 53: 206–34.
37.
HoganC.M., GrantM.Physiologic mechanisms of nausea and vomiting in patients with cancer. Oncol Nurs Forum.1997; 24(7 suppl):8–12.
38.
HaslerW.L.Approach to the patient with nausea and vomiting. In: HumesH.D., ed. Kel-ley's Textbook of Internal Medicine.4th ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2000; 729–38.
39.
BorisonH.L., McCarthyL.E.Neurophar-macology of chemotherapy-induced emesis. Drugs.1983; 25(suppl 1): 8–17.
40.
Del FaveroA., RoilaF., TonatoM.Reducing chemotherapy-induced nausea and vomiting: Current perspectives and future possibilities. Drug Saf.1993; 9: 410–28.
41.
Mosby's GenRx.The complete reference for generic and brand drugs.St. Louis, MO: Mosby Inc.; 1999.
42.
DiemunschP., GrelotL.Potential substance P antagonists as antiemetics. Drugs.2000; 60, 533–46.
43.
GrunbergS.M., HeskethP.J.Control of chemotherapy-induced emesis. N Engl J Med.1993; 329: 1790–6.
GravesT.Chemotherapy-induced nausea and vomiting: Treatment options. Hosp Formul.1991; 26: 474–88.
46.
MorrowG.R., RoscoeJ.A., KirshnerJ.J.Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer.1998; 6: 244–7.
47.
GoodmanM.Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting. Oncol Nurs Forum.1997; 24(7 suppl):20–32.
48.
TaylorA.T.Nausea and vomiting. In: DiPiroJ.T., TalbertR.L., YeeG.C.., eds. Pharmacotherapy. A Pathophysiologic Approach.4th ed.Stamford, CT: Appleton & Lange; 1999, 586–98.
49.
EttingerD.S.Preventing chemotherapy-induced nausea and vomiting: An update and a review of emesis. Semin Oncol.1995; 22(4 Suppl 10):6–18.
50.
MorrowG.R., RoscoeJ.A., HynesH.E.Progress in reducing anticipatory nausea and vomiting: A study of community practice. Support Care Cancer.1998; 6: 46–50.
51.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–9.
52.
MartinM.The severity and pattern of emesis following different cytotoxic agents. Oncology.1996; 53(suppl 1): 26–31.
53.
SchoenikeS.E., DanaW.J.Ifosfamide and mesna. Clin Pharm.1990; 9: 179–91.
54.
HrusheskyW.J.M.The clinical application of chronobiology to oncology. Am J Anat.1983; 168: 519–42.
55.
RoemelingR.V., ChristiansenN.P., HrusheskyJ.M.Lack of antiemetic effect of high-dose metoclopramide. J Clin Oncol.1985; 3: 1273–6.
56.
SchmollH.J., CasperJ.Management of other non-cisplatin-induced emesis. Oncology.1996; 53(suppl 1): 51–5.
57.
MorrowG.R.Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol.1984; 2: 1170–6.
58.
Cancer Therapy Evaluation Program. Common Toxicity Criteria. Version 2. Available online at http://ctep.info.nih.gov/CTC3/ctc.htm. Bethesda, MD: National Cancer Institute. Accessed November 8, 2000. Updated April 1999.
59.
FettingJ.H., GrochowL.B., FolsteinM.F.The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep.1982; 66: 1487–93.
60.
GrallaR.J., OsabaD., for the American Society of Clinical Oncology et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17: 2971–94.
61.
MerrifieldK.R., ChaffeeB.J.Recent advances in the management of nausea and vomiting caused by antineoplastic agents. Clin Pharm.1989; 8: 187–99.
62.
KemenyN., DalyJ., ReichmanB.Intrahepatic or systemic infusion of fluo-rodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med.1987; 107: 459–65.
63.
Floxuridine. In: DorrR.T., Von HoffD.D., eds. Cancer Chemotherapy Handbook.2nd ed.Norwalk, CT: Appleton & Lange; 1994, 489–95.
64.
KrautE.H., BouroncleB.A., GreverM.R.Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol.1989; 7: 168–72.
65.
SpiersA.S.D., MooreD., CassilethP.A.Remissions in hairy-cell leukemia with pen-tostatin (2′-deoxycoformycin). N Engl J Med.1987; 316: 825–30.
66.
EttingerL.J., KurtzbergJ., VouteP.A.An open-label, multicenter study of polyethylene glycol-l-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer:1995; 75: 1176–81.
